Orchard Therapeutics plc Analytics - Traffic, Statistics and Competitor Tracking

Orchard Therapeutics plc Website Screenshot


Orchard Therapeutics plc Company Intro

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type MPS-IIIA and OTL-202 for mucopolysaccharidosis type IIIB. Orchard Therapeutics plc entered into a manufacturing and technology development agreement with MolMed S.p.A. to develop, manufacture and supply certain viral vectors and conduct cell processing activities for certain Orchard development and commercial programs. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is based in London, the United Kingdom.



Orchard Therapeutics plc Headquaters

108 Cannon Street
London,EC4N 6EU
United Kingdom

Orchard Therapeutics plc Share price

14 May 2021 02:19 GMT


0.12 (2.27 %)

Orchard Therapeutics plc Market cap

$697.46 M



Orchard Therapeutics plc # 234


Latest Orchard Therapeutics plc News

WMC Market Score

WMC Market to Revenue Score

Orchard Therapeutics plc Market Financials

Revenue, Expenses, Profit

Company Currency Revenue Expense Profit Market Cap WMC Sector Score
Orchard Therapeutics plc USD $2,513 $174,581 $-163,422 $6,975M 234
Regeneron Pharmaceuticals, Inc. USD $9,243,500 $5,152,600 $3,156,000 $540,220B 1
Vertex Pharmaceuticals Incorporated USD $6,205,683 $2,599,993 $2,711,647 $550,560B 2
Alexion Pharmaceuticals, Inc. USD $6,069,900 $2,656,500 $603,400 $380,130B 3
Incyte Corporation USD $2,229,409 $1,622,822 $446,906 $181,110B 4

Market Analytics

Company Search vs Top 4 Industry Competitors

Total Orchard Therapeutics plc Social Followers vs Top 4 Industry Competitors

Orchard Therapeutics plc Post vs Top 4 Industry Competitors

Orchard Therapeutics plc Digital Footprint By Size vs Top 4 Industry Competitors

Orchard Therapeutics plc Digital Footprint By Change Rate vs Top 4 Industry Competitors

Orchard Therapeutics plc WMC Market Score Calculations

Details Revenue Total Social Followers Total Social Posts Search Volume Digital Footprint Size Digital change (New Pages) WMC Market Score
Orchard Therapeutics plc 0.03 32.24 1.00 0 0 0 12.93
Regeneron Pharmaceuticals, Inc. 100 23.93 2.32 100 0 0 48.53
Vertex Pharmaceuticals Incorporated 67.14 34.98 0.73 86 0 0 46.73
Alexion Pharmaceuticals, Inc. 65.67 100 100 60 0 0 100
Incyte Corporation 24.12 4.93 0.05 2 0 0 2.85

Book a demo

Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.

* required fields

You'll learn how to:

  • 1. Automatically monitor your entire digital landscape including competitors
  • 2. View all new industry activity in real time
  • 3. Monitor your position in your industry
  • 4. Enrich your reports and strategy
  • 5. Empower your teams with knowledge

Our platform is loved & trusted by avariety
of world-leading brands

  • unilever
  • wavesight
  • acca
  • abeerdeen
  • UK2
  • umbo
  • rb